ERAS

Erasca, Inc.

• Benzinga·18h ago

  Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday

• TipRanks·2d ago

  Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Erasca (ERAS)

• Simply Wall St·5d ago

  Erasca (ERAS) Is Up 9.9% After Merck Tie-Up And IP Challenge To ERAS-0015 - Has The Bull Case Changed?

• PR Newswire·6d ago

  Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset

• Simply Wall St·6d ago

  Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus

• PUBT·05/19 00:15

  Erasca releases corporate presentation outlining RAS/MAPK cancer drug pipeline

• Seeking Alpha·05/17 11:29

  Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

• Simply Wall St·05/16 14:38

  Assessing Erasca (ERAS) Valuation After ERAS-0015 Patent And Trade Secret Dispute

• TipRanks·05/14 16:11

  Adlai Nortye initiated with a Buy at JonesResearch

• TipRanks·05/14 12:12

  J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

• Simply Wall St·05/13 20:59

  The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift

• Seeking Alpha·05/12 15:01

  Healthcare stocks with A+ momentum investors are watching

• Dow Jones·05/12 13:11

  Erasca Price Target Cut to $26.00/Share From $28.00 by Mizuho

• Dow Jones·05/12 13:11

  Erasca Is Maintained at Outperform by Mizuho

• Benzinga·05/12 13:01

  Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26